or Try an Advanced Search...

    Growth Hormone Deficiency Stocks List

    Symbol Grade Name % Change
    RANI F Rani Therapeutics Holdings, Inc. -0.49
    LLY F Eli Lilly and Company -1.66
    ASND F Ascendis Pharma A/S -1.40
    LUMO B Lumos Pharma, Inc. 0.23
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Growth Hormone Diabetes Biopharmaceutical Biotechnology Growth Hormone Therapy Hypertension Life Sciences Osteoporosis Peptide Hormones Pulmonary Arterial Hypertension Acromegaly Alzheimer's Disease Amyloid Animal Health Animal Health Products Antibiotics Attention Deficit Hyperactivity Disorder Bacterial Infections Benign Prostatic Hyperplasia Bipolar Depression

    Related ETFs - A few ETFs which own one or more of the above listed Growth Hormone Deficiency stocks.

    Symbol Grade Name Weight
    MEDI D Harbor Health Care ETF 23.66
    IHE D iShares U.S. Pharmaceutical ETF 20.67
    MEDX F Horizon Kinetics Medical ETF 15.83
    THNR F Amplify Weight Loss Drug & Treatment ETF 14.71
    OZEM F Roundhill GLP-1 & Weight Loss ETF 14.13
    View all Growth Hormone Deficiency ETFs...
    Compare ETFs
    Compare IHE to THNR Compare MEDI to IHE Compare THNR to OZEM

        Growth Hormone Deficiency Stocks Recent News

        Date Stock Title
        Nov 21 LLY Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
        Nov 21 LLY Hims & Hers closes up 10% as Lilly tirzepatide compounding dispute resolution delayed
        Nov 21 LLY Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
        Nov 21 LLY Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
        Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
        Nov 21 LLY Versant startup sets out to make a new type of obesity drug
        Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
        Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
        Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
        Nov 20 LLY More companies covering weight loss drugs for their employees
        Nov 20 LLY Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
        Nov 20 LLY China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
        Nov 20 LLY Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk
        Nov 20 LLY Is It Time to Sell Eli Lilly and Pfizer Stocks?
        Nov 20 LLY The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley
        Nov 20 LLY Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
        Nov 20 RANI RANI: Third Quarter Update
        Nov 20 LLY RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
        Nov 19 LLY Lilly announces changes on board of directors
        Nov 19 LLY Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Growth Hormone Diabetes Biopharmaceutical Biotechnology Growth Hormone Therapy Hypertension Life Sciences Osteoporosis Peptide Hormones Pulmonary Arterial Hypertension Acromegaly Alzheimer's Disease Amyloid Animal Health Animal Health Products Antibiotics Attention Deficit Hyperactivity Disorder Bacterial Infections Benign Prostatic Hyperplasia Bipolar Depression
        Growth Hormone Deficiency

        Growth hormone deficiency (GHD) is a medical condition in which the body does not produce enough growth hormone (GH). GH is a hormone produced by the pituitary gland that is essential for normal growth and development. GHD can cause a variety of symptoms, including short stature, delayed puberty, and decreased muscle mass. Treatment for GHD typically involves hormone replacement therapy, which can help to restore normal growth and development.

        Browse All Tags